Peer-reviewed veterinary case report
Long-term outcomes of ovarian tumor treatment in seven dogs
By Itoh, Teruo et al.·Published in Journal of the American Animal Hospital Association·2021·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-Term Treatment Results for Ovarian Tumors with Malignant Effusion in Seven Dogs.
- Species:
- dog
Plain-English summary
A group of seven dogs with ovarian tumors and fluid buildup in their abdomen were treated with surgery to remove the ovaries and uterus, followed by chemotherapy. After surgery, the fluid in all dogs resolved, and six of them received additional chemotherapy with carboplatin. Dogs with granulosa cell tumors had a better outcome, with some living over 1,800 days without recurrence, while those with ovarian adenocarcinoma faced more challenges, including fluid returning after surgery. Overall, the study suggests that these treatments can help dogs with ovarian tumors live longer, especially if they have granulosa cell tumors.
People also search for: dog ovarian tumor treatment · dog abdominal fluid after surgery · chemotherapy for dog ovarian cancer
Abstract
Surgery and platinum-based chemotherapy are highly efficacious for treating advanced ovarian cancers in humans, but their efficacy is less known in dogs. We evaluated the long-term treatment outcomes of seven dogs with malignant ovarian tumors with malignant abdominal effusion. Ovariohysterectomies (OVHs) were performed on all dogs; four had ovarian adenocarcinoma (AC) with gross dissemination in the peritoneum (two with pleural effusion), and three had a granulosa cell tumor (GCT) with no gross dissemination in the peritoneal cavity, although one showed pleural effusion. Effusion resolved after the OVH in all dogs. Six dogs (three ACs, three GCTs) received postoperative IV carboplatin therapy. Two dogs with GCT had no postoperative recurrence or metastasis, and one dog with GCT had recurrence 1811 days postoperatively. All dogs with AC developed recurrent effusion 171-584 days postoperatively, which resolved after intracavitary administration of cisplatin or carboplatin, with a subsequent disease-free interval of 155-368 days. Overall survival was longer for dogs with GCTs (822-1840 days) than for those with ACs (617-841 days). These results suggest that dogs with ovarian tumors with malignant effusion can survive relatively long after platinum-based chemotherapy in addition to OVH, with a more favorable prognosis for GCT than AC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33770181/